CSF1R and neoplasm: A preclinical study of PLX3397, a selective c-Fms and c-kit inhibitor, combined with rapamycin, a TORC1 inhibitor, to deplete tumor-promoting macrophages, showed efficacy with an overall reduction in MPNST cell proliferation [129].